1. Introduction
Cardiac fibroblasts (CFs) are mesenchymal in nature. CFs originating from the
pro-epicardial organ through epithelial to mesenchymal transition (EMT) are
referred to as epicardial fibroblasts [1], whereas CFs originating from
endothelial cells by endothelial to mesenchymal transition (EndMT) are referred
as endocardial fibroblasts [2]. Depending on their location and function, CFs can
be broadly classified into interstitial septal and ventricular fibroblasts,
adventitial septal and ventricular fibroblasts, atrial fibroblasts, annulus
fibroblasts and cardiac valve fibroblasts [3]. CFs produce different components
to maintain heart structure, such as periostin (Postn), vimentin, fibronectin and
collagen types I, III, V and VI [4], and can be identified through certain
markers such as cluster of differentiation 90 (CD90), discoidin domain receptor 2
(DDR2), fibroblast specific protein-1 (FSP-1), spinocerebellar ataxia type-1
(Sca1), fibronectin, vimentin and collagen types I and III [5]. Certain markers
upregulate during cardiac fibrosis, such as fibroblast activating protein (FAP),
fibroblast specific protein (FSP), fibronectin splice variant extra domain- A
(ED-A), alpha smooth muscle actin (-SMA), transcription factor 21
(Tcf21) and receptor tyrosine kinase platelet derived growth factor A
(PDGFR) [6]. Among these, -SMA is the marker used for
activated fibroblast identification. Tcf21 and PDGFR are expressed by
CFs during cardiac epicardial development [7]. CFs are distributed throughout the
heart, where, predominantly present in the annulus fibrosus and adventia of
coronary arteries and hence referred as valvular fibroblasts [8]. There are also
more organized fibroblasts around the sinoatrial node which contribute to
insulating the electric impulse [9]. Further, the fibroblasts are mainly present
in coronary vessels [10]. The fibroblasts located between muscle fibres and
referred as interstitial CFs and are less functional in the cardiac
microenvironment [11]. CFs are the major source for ECM regulation, synthesis and
degradation. They secret various collagens (I, III, IV, V and VI) to form ECM
[12]. CFs, secrete a great number of proteins such as fibronectin, elastin,
laminins, fibrillins, glycoprotein and proteoglycans, which are essential for ECM
organization and cardiac signaling [13]. They also play roles as paracrine
signals during the communication between CFs and other cardiac cells such as
cardiomyocytes, endothelial cells and immune cells in the cardiac
microenvironment [14]. ECM composition influences the response of fibroblasts to
growth factors such as transforming growth factor beta (TGF-) and
induces its transition to myofibroblasts (MFBs) [15]. In myocardial infarcted
heart, CFs at the initial stage of the inflammatory phase secrete matrix metallo
proteinases (MMPs) which degrade ECM and promote cell migration to infarcted
areas [16]. However, myocardial fibrosis induced by CFs plays a dual role in
cardiac remodeling after injury. CFs are activated and deposit ECM at the injured
part to heal the wound [13], but protracted inflammation can increase scarring
and retard wound healing, causing cardiac dysfunction [17]. CFs are one of the
major groups of cells present in cardiac tissue. In this review the development
and function of CFs, and the crosstalk between CFs and cardiac stromal cells are
discussed, especially the role of CFs functioning in electrophysiology and the
induction of senescence. While several what we know about CFs has been derived
from in vitro studies, there are also illuminating in future research. This
review aims to raise a path to fill in the gaps of present studies, and to help
better understand the role of CFs-in cardiac diseases.
2 Transition and differentiation of cardiac fibroblasts to cardiac
myofibroblasts
CFs under the influence of several cardiac stressors such as physical stretch,
cardiac stress, growth factors, and inflammatory mediators activate and convert
to the MFB phenotype [18]. Prior to conversion of CFs to MFBs cells undergo an
intermediate stage, the proto-myofibroblast phenotype. These,
proto-myofibroblasts differ from MFBs by impaired expression of -SMA
[19]. These cells have migratory capacity by enhanced formation of stress fibers
that facilitate contraction, while this phenomenon is not observed in
non-activated fibroblasts [20]. CF conversion to MFBs is influenced by the
TGF- – Smad signalling pathway. TGF- activates fibroblasts
through phosphorylation of Smad2 or Smad3 and forming a complex with Smad4, then
this complex translocates to the nucleus and subsequently binds and activates ECM
genes such as collagen-I[18]. CF activation is also triggered by
several growth factors such as connective tissue growth factor (CTGF/CCN2),
angiotensin-II and platelet derived growth factor [21]. Certain intracellular
signalling mediators such as, the a smad repressor- zinc finger E- box binding
homeobox2 (Ski-Zeb2) – mesenchyme homeobox2 (Meox2) pathway, calcineurin/nuclear
factor of activated T-cells (NFAT) and P38 induce transition of CFs to
MFBs [22]. Apart from these, mechanical stretch of CFs transitions them to MFBs
[23]. The differentiation between CFs and cardiac MFBs is challenging because of
the lack of specific biomarkers. There are certain markers, such as vimentin,
cluster of differentiation 31, 45 (CD31, CD45) and FSP-1, that are expressed by
CFs and also by other cardiac cells such as, endothelial cells and macrophages
[24, 25]. Also, there are certain markers that are expressed by CFs and cardiac
MFBs such as transcription factor 21 (Tcf 21), osteopontin, frizzled-2 and DDR2
[12, 24, 26]. However, certain markers such as, platelet derived growth factor-
alpha (PDGF-), collagen1a1- green fluorescent protein (GFP) and
cadherin-11 express on CFs but their expression on cardiac myofibroblasts needs
to be clarified [24]. A few markers, such as transforming growth factor-
type-II receptor, angiotensin 1 receptor, tensin, paxillin, fibronectin, tenascin
C and Postn show upregulated expression by MFBs during specific pathological or
stress conditions [27]. However, currently -SMA is used as the standard
biomarker to differentiate cardiac MFBs and CFs because its expression is
peculiar to stressed conditions and it is specifically not expressed by CFs [28].
Recent studies revealed a biomarker that is expressed on human CFs and cardiac
MFBs, i.e., sushi containing domain 2 (SUSD2). Cultured CFs co-express SUSD2 with
fibroblast marker PDGFR[29].
3. Cardiac fibroblasts in development of pre-natal and post-natal
heart
Cardiac development, also referred to as cardiogenesis, is an important
physiological process during mammalian embryonic development. The heart is the
first functional organ developed during embryonic development [30]. At the 4th
week of gestation, epicardial epithelial cells undergo EMT and form CFs and the
vascular smooth muscle cells of matured hearts [31]. Cardiomyocytes, CFs,
endothelial cells and valvar interstitial cells are the major cardiac cells
during embryonic heart development [32]. Cells expressing genes such as
collagen type 1 alpha (COL1A1), COL1A2,
COL3A1, Postn and decorin (DCN) are represented as CFs
in the embryonic heart. Their main function is formation of ECM [13]. CFs express
four different gene groups during the developmental stage. The first associates
with striated muscle cell development, with expression upregulated in mid and
late stages of development [33]. At 17 weeks gestational stage development,
fibroblasts express SRY-Box transcription factor-9 (SOX9) a sarcomere protein,
i.e., cardiac troponin T [33]. At this stage there is a severe change in the cell
cycle. The expression of cell cycle genes is significantly reduced during
development suggesting the reduction of CF proliferation during heart
development. The mitotic genes aurora kinase B (AURKB),
cyclin dependent kinase 1 (CDK1) and ubiquitin
conjugating enzyme EC (UBEC) are downregulated, together
with the upregulation of ECM deposition related genes such as DCN and
COL3A1 etc., showing upregulated expression in the early- to mid-stage
of heart development [33]. Thus ECM deposition is essential to maintain the
structure and promote cell to cell interaction in the cardiac microenvironment.
ECM expression is upregulated in week 5 to week 6 of the gestational period.
Furthermore, fibroblasts could upregulate the expression of the bone morphogenic
protein (BMP) signaling pathway during development [33] through increasing the
expression of BMP signaling pathway receptors such as bone morphogenic protein
receptor type 2 (BMPR2), activins A receptor (ACVR), drosophila mothers against
decapentaplegic protein (SMAD) and SMAD which are essential for cell
to cell communication during cardiac development [33].
During postnatal development the interactions between the cells in the cardiac
microenvironment through several signaling pathways contributes to heart
development and disease [34]. CFs facilitate cardiomyocyte maturation by
upregulated expression of certain genes such as DCN, laminin
subunit gamma 1 (LAMC1), placental growth factor
(PGF) and laminin subunit alpha-2 (LAMA2) to secrete
maturation promoting proteins which can bind to the receptor on cardiomyocytes
and promote maturation [35]. Furthermore, the BMP signaling pathway between CFs
and cardiomyocytes initiates maturation of cardiomyocytes prominently, and there
are other common pathways activated by cardiac fibroblasts such as fork head box
O (FOXO), mechanistic target of rapamycin (mTOR), and vascular endothelial growth
factor (VEGF) that contribute to switching of the heart from neonatal to
post-natal matured heart [35]. There are critical changes in heart following
birth. Heterogeneous cardiac fibroblasts populations exist from the third day
after birth. These fibroblasts express different endogenous genes such as
Postn and Tcf21. -SMA is also expressed by MFBs,
which is essential for ECM remodeling after birth. Postn’s expression is
persistent until postnatal day 30 (P30), but is downregulated when Tcf21 is
expressed. Based on these gene expressions, CFs are of these groups: Postn
expressing at postnatal day 7 (PostnP7), Tcf21 expressing at postnatal day
7 (Tcf21P7) and Tcf21 expressing at postnatal day 30 (Tcf21P30).
PostnP7 and Tcf21P7 are no longer detected at P30, but Tcf21P30 CFs downregulates ECM expression and remains quiescent at P30. Postn
CFs also remain quiescent but are activated after injury to perform cardiac
repair. There is a need to know Postn CFs’ interaction with other CFs in
cardiac microenvironment in the repair mechanism [36].
4. The cross talk between fibroblasts and cardiac stromal cells
The cardiac microenvironment is composed of several cell types: 60–70% of
non-myocytes such as endothelial cells, vascular smooth muscle cells and
fibroblasts; 30–40% of cardiomyocytes responsible for the contractility of
heart muscles [37]. These cells interact with each other due to alterations in
development, homeostasis and pathological triggers.
4.1 Cardiac fibroblasts and cardiomyocytes
CFs and cardiomyocytes interconnect through cell-to-cell communication directly
or indirectly by expressing cytokines and other mediators via the autocrine or
paracrine pathway during pathological stress [38]. In in vitro
conditions, expression of tumor necrosis factor alpha (TNF-) in CFs was
upregulated under hypoxic conditions, instead of interleukin 1 beta
(IL-1), IL-10 and interferon gamma (INF-), to reduce the
threshold for mitochondrial permeability transition (MPT) induction by reactive
oxygen species (ROS) in cardiomyocytes, causing the apoptosis of cardiomyocytes
and the decrease of CF proliferation, in turn resulting in aggravation of
ischemia reperfusion injury (Fig. 1) [39]. Meanwhile, hypoxic cardiomyocytes
secrete some metabolites like IL-1, TNF- and IL-6, among them
IL-1 and TNF- depending on in vitro exposure time
intervals, contributing to fibroblast migration prior to myocardial damage.
Prolonged hypoxic conditions upregulate transforming growth factor beta
(TGF-), a pleiotropic cytokine that contributes to cardiac repair and
remodeling by significant inhibition of fibroblast migration [40, 41]. C1q/tumor
necrosis factor related protein (CTRP) expression is compromised in
cardiomyocytes of the left ventricle of mice that underwent transverse aortic
constriction (TAC), but in pressure overloaded mice CTRP15’s expression is
upregulated by adeno associated virus (AAV9), which contributes to downregulation
of profibrotic molecule TGF-1 through the Smad3 pathway. Moreover,
CTRP15 augments the phosphorylation of insulin receptor (IR) and causes the
activation of protein kinase B (AKT), which results in an antifibrotic
effect (Fig. 1). There is a need to elucidate the mechanism in
upregulation of IR by CTRP15 [42]. However, in clinical studies M
(a non-glycosylated protein) over expression by cardiomyocytes promotes the
activation of CFs through epidermal growth factor receptor (EGFR) signaling under
pressure overload, which causes cardiac dysfunction in hypertension and heart
failure patients [43]. Metabolites such as hypoxia induced mitogenic factor
(HIMF) overexpression in cardiomyocytes influences the activation of CFs.
Moreover, in mice HIMF also stimulates IL-6’s secretion of CFs, but blocking of
IL-6 downregulates HIMF’s expression. IL-6 in cardiomyocytes and fibroblasts
activated mitogen activated protein kinase (MAPK) and calcium/calmodulin
dependent kinase II (CaMKII)-signal transducer and the activator of transcription
3 (STAT3) pathway, which stimulates activation of fibroblasts and hypertrophy of
cardiomyocytes resulting in promotion of fibrosis and cardiac hypertrophy [44].
Follistatin-like 3 (FSTL3) was overexpressed by cardiomyocytes under a stress
condition, which induced CF activation and proliferation and led to progression
of disease [44]. -SMA negative fibroblasts in normal heart cause
reduction of adult cardiomyocyte viability through paracrine signaling, but
cardiomyocytes, along with TGF-, secrete other metabolites that affect
CF proliferation [45]. In mice, the suppression of plasma membrane calcium ATPase
4 (PMCA4)’s expression in fibroblasts causes increased expression of nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-kB) and paired box
gene 2 (Pax2), where Pax2 is the major transcription factor for secreted frizzled
related protein 2 (SFRP2) expression, and its upregulation would inhibit the Wnt
pathway and then suppress hypertrophic responses in cardiomyocytes. Here, there
is a need to know PMCA4 action on endothelial and smooth muscle cells, which
could further contribute to therapeutics [46]. CFs secrete star microRNA (miRNAs)
enriched exosomes due to stress signals, and these exosomes act upon
cardiomyocytes by paracrine signaling to downregulate expression of sorbin and
SH3 domain containing 2 (SORBS2) and PDZ and LIM domain 5 (PDLIM5) (Fig. 1).
Under normal conditions, SORBS2 is essential for the assembly of myofibrils and
several other important processes in cardiomyocytes, and PDLIM5 is required for
maintenance of cardiac muscle structure and function. So the downregulation of
SORBS2 and PDLIM5 by miR-21 would contribute to cardiac failure caused by
myocardial hypertrophy [47]. In vitro and in vivo studies
reveal that cardiomyocytes secreted exosomes containing miR-208a were up taken by
CFs. These exosomes induce proliferation of fibroblasts and also trigger their
transition to MFBs. These effects are mediated by miR-208a through upregulation
of dual specificity tyrosine phosphorylation regulated kinase-2v (DYrk2)
expression that induces phosphorylation of NFAT, causing cessation of its entry
into the nucleus resulting in induction of fibrosis [48].
Fig. 1.
Cardiac fibroblasts and cardiomyocytes interaction with and
endothelial cells. CFs interact with cardiomyocytes either to promote or
suppress the disease. CF autocrine and paracrine interaction by release of
certain cytokines facilitates cell to cell communication. The secretions of other
cardiomyocytes also influence fibroblast activation and attain myofibroblast
phenotype.
4.2 Cardiac fibroblasts and endothelial cells
Endothelial cells (ECs) are an elementary part of the vasculature and the heart,
where cardiac ECs could modulate performance of cardiac muscles [49]. Endocardial
ECs release cytokines like TGF-, Endothelin 1 (ET-1) and angiotensin II
(Ang-II). Among these, ET-1 stimulates CF proliferation via the MAPK/(mitogen
activated protein kinases/extracellular signal-regulated kinases) ERK pathway,
which is involved in the progression of fibrosis by collagen synthesis (Fig. 2)
[50]. Zinc finger protein SNAl1 (Snail) expressed by endothelial cells could
induce EndMT and stimulate differentiation of CFs to MFBs in a mouse ischemia
reperfusion injury model (I/R injury). Meanwhile, the expression of connective
tissue growth factor (CTGF) as a profibrotic factor is also upregulated in
correspondence with Snail, following the secretion of -SMA and smooth
muscle 22 alpha (SM22) as mesenchymal components to induce the
migration of fibroblasts (Fig. 2) [51]. However, Ly6/PLAUR domain containing
protein (LYPD) upregulated expression in CFs restrains vascular network formation
of human vascular endothelial cells (HUVECs) [51], which exhibit cardiac
dysfunction caused by the interaction between CFs and endothelial cells. In
recent studies TGF- activated CFs secrete altered exosomes, i.e.,
miR-200a-3q which modifies angiogenic potential, proliferation and migration of
endothelial cells. These exosomes regulate phosphatidylinositol glycan anchor
biosynthesis class F (PIGF)-dependent vascular endothelial growth factor
A(VEGF-A) signalling which induces dysfunction of endothelial cells. Inhibiting
miR-200a-3q in MFBs restores endothelial function [52]. There is a need for
further exclusive study of several autocrine and paracrine factors and mechanisms
that are hidden in the interaction between CFs and endothelial cells.
Fig. 2.
Cardiac fibroblasts and endothelial cells interaction.
Endothelin-1 and Snail expression by endothelial cells in the cardiac
microenvironment activate fibroblasts and facilitate activated fibroblast
conversion to myofibroblasts through -SMA. Increased Ly6/PLAUR domain
containing protein (LTPD) in fibroblasts restrains vascular network formation of
human vascular endothelial cells (HUVEs).
4.3 Cardiac fibroblasts and cardiac macrophages
Macrophages are the key cells that induce inflammation in cardiac injury and
cardiac repair [53]. CFs and macrophages interact with each other through several
cytokines’ paracrine activity [54]. Studies on patients with rheumatic heart
disease with mitral/aortic valve replacement discover that Ang-II induced
fibroblast proliferation caused by upregulated expression of Toll/IL-1 receptor
domain containing adaptor (TRIF) during atrial fibrillation. Upregulated TRIF
could increase macrophage infiltration into atrial fibroblasts by chemotaxis
induction via c-c motif Chemokine ligand 2 (CCL2), CCL7, CCL12 and c-x-c motif
Chemokine ligand 10 (CXCL10). These macrophages associate with atrial fibroblast
proliferation and result in fibrosis [55]. In myocardial infarction (MI) induced
mice, there is an increased number of CD206F4/80CD11b M2-like
macrophages stimulating CFs transformation into MFBs through increasing the
expression of IL-4 post MI. Simultaneously, IL-1 and osteopontin (Sppl)
are also nearly 3-fold upregulated to stimulate the activation of fibroblasts and
result in repair of post-MI hearts [56]. In mice, induced acute myocardial
infarction (AMI) studies revealed that mir-155 upregulated expression in
macrophages is influenced by lipopoly saccharides (LPS) and Ang-II. Activated
macrophages release exosomes enriched with mir-155, which inhibits cardiac
fibroblast proliferation by suppressed expression of son of seven less homolog 1
(Sos1) protein causing impaired cardiac repair after MI (Fig. 3). Sos1
is a prominent protein that interacts with growth factor receptor bound protein 2
(Grb2) and stimulates cell proliferation by activating ERK [57]. Clinical studies
on cardiac rupture (CR) in AMI reveal that S100A8/A9 is overexpressed by
macrophages in peripheral blood and myocardial tissue. S100A8/A9 interacts with
advanced glycation end products (RA-GE) and Toll-like receptor 4 (TLR-4)
stimulates migration and activation of macrophages. Moreover, TNF- overexpressed by macrophages causes upregulated expression of NF-kB and matrix
metallopeptidase 9 (MMP-9) in human CFs leading to degradation of ECM followed by
CR [58]. Particularly, our studies on experimental autoimmune myocarditis (EAM)
and viral myocarditis-induced mice reveal that cardiac resident macrophages play
a prominent role in homeostasis, maintenance of cardiac function and tissue
repair. Ang-II induces transdifferentiation of CFs to MFBs, and these MFBs could
secrete leptin to promote M1/M2 macrophages conversion through the
phosphoinositide-3-kinase (PI3K) or the AKT pathway (Fig. 1). M1 macrophages
perform apoptosis through the TNF/tumor necrosis factor-1 (TNFR1) axis resulting
in suppression of inflammation. Simultaneously, converted M2 macrophages reside
in the heart and promote anti-inflammatory responses [59]. In myocarditis-induced
mice, high expression of IL-17A in CFs stimulates increased expression of
granulocyte macrophage colony stimulating factor (GM-CSF) which suppresses
lymphocyte antigen 6 low (Ly6C) monocyte differentiation to macrophages,
but activates lymphocyte antigen 6 high (Ly6C) monocytes derived
macrophage (MDMs), and causes activation of inflammation, promotion of tissue
remodeling and reduction of phagocytosis, and thereby myocarditis related heart
failure (Fig. 3) [60]. In a transverse aortic constriction (TACn) mouse model,
LY6C monocytes accumulate in cardiac hypoxic areas by hypoxia inducible
factor 1-alpha (HIF-) signaling, which overexpress oncostatin-m (OSM)
to target TGF-1 mediated CF activation through extracellular signal
regulated kinase1/2 dependent phosphorylation of the SMAD liker region. Thus OSM
could suppress excessive fibrosis in hypoxic cardiac tissue [61]. Studies in a
cardiac injury mouse model reveal that macrophages express collagen and collagen
associated genes that caused collagen fiber deposition in forming scar, which
suggests that macrophages participate directly in cardiac fibrosis [62]. In the
mouse model, different macrophage subsets show different effects on CFs in
cardiac fibrosis. Ma, Mc and M phenotype show antifibrotic
activity, but Mb and M phenotype show profibrotic activity. Ma
macrophages trigger cardiac fibroblasts to express CTGF, and then cause
proliferation, migration, and differentiation to MFBs. Mc macrophages
accelerate Ma function through upregulated expression of -SMA.
However, Mb macrophages exert roles opposite to those of Ma and
Mc, even though Mb macrophages show beneficial action in the early
stage after myocardial I/R injury by regulating MAPK signaling. Late stage
Mb macrophages are dominated by M macrophage and cause severity of
the disease. There is a need to elucidate the relation between Mb and MAPK
signaling and CFs, so it is necessary to clarify Mb interrelations with
other signaling pathways [63]. CFs secrete hyaluranan (HA) by Has in I/R
injury, where the downregulation of Has caused reduction of -SMA
positive fibroblasts, resulting in decrease of MFB differentiation and
proliferation (Fig. 3), and the blockade of CD44 as HA’s receptor would inhibit
TGF-1-specific responses like SMAD2 phosphorylation, causing hampered
secretion of -SMA secretion. Moreover, the decrease of hyaluronan
synthase-2 (Has) could induce apoptosis of macrophages, which
indicates that HA plays a prominent role in post-infarct healing [64].
Macrophages could upregulate expression of TGF- and metalloproteinase
such as MMP2, MMP9 and MMP12 in Chagas disease (CD) caused by
Tryoanosomacruzi, due to differentiation of CFs to MFBs. Upregulation of
poly [adenosine diphosphate ribose (ADP)-ribose] polymerase 1/activator protein-1
(PARP1/AP-1) in infected macrophages results in transcriptional activation of
MMP/TGF- responses in macrophages by c-Fos and Jun B mediated AP-1,
followed by development of cardiac fibrosis [65]. Studies in mice have confirmed
the phenotypic transition of infiltrating macrophages to fibroblastic-like cells
post MI, according to the upregulation of fibroblast markers such as type-I
collagen, prolyl-4-hydroxylase, fibroblast specific protein-1 and fibroblast
activation protein in macrophages in the heart after MI. Macrophage transition to
fibroblasts improves cardiac regeneration after MI. In this regard, continued
research into the transition of tissue resident macrophage merits further
exploration [66].
Fig. 3.
Cardiac fibroblasts and cardiac macrophages interaction. CFs
proliferates by stimulation with ANG-II and secretes certain cytokines that
triggers infiltration of macrophages. Hyaluronan (HA) secretion downregulates
expression of -SMA and results in conversion of CFs to myofibroblasts.
CFs secreted IL-17A upregulates GM-CSF that inhibits LY6C monocytes
conversion to macrophages and induces LY6C monocyte conversion to
macrophages. Cytokines secreted by macrophages convert CFs to myofibroblasts,
leptin secreted by myofibroblasts converts M1 macrophages to M2 macrophages
through P13K/AKT signaling. The secretion of IL-1 and Spp1 by
macrophages causes activation of fibroblasts, TNF- secretion
upregulates NF-kB and MMP-9 expression in CFs and causes degradation of ECM.
Green fluorescent protein transgene (GFPtpz) expression causes collagen deposit.
5. Cardiac fibroblasts in cardiac electrophysiology
Electrophysiology is a test performed to understand proper electrical
functioning of the heart. In the heart, atrial and ventricular muscles follow a
synchronized pattern of rhythmic contraction and relaxation, represented as
depolarization and repolarization of heart due to electrical activity [67]. These
electrical signals are generated from the sinoatrial node (SA), also referred as
the pacemaker of the heart. These electrical activities of the heart are recorded
by a medical device referred to as an electrocardiograph (ECG) [68]. Normally,
the major cardiac cell groups such as cardiomyocytes actively contribute to the
electrophysiology of the heart, while CFs as non- electrical cells or non-
beating cells could decrease the synchronization of cardiomyocytes [69]. CFs can
connect cardiomyocytes through intercellular communication and decrease the
velocity of electrical signaling. Excessive CFs cause less synchronization,
influencing the rhythm of the heart beat [70]. Upon cardiac injury, healing
progresses by cardiomyocytes as opposed to CFs. CFs due to injury convert to
-SMA expressing MFBs and result in deterioration of heart function.
Here, connexin 43 is qualitatively observed proving the cell to cell
communication [71]. CFs co-cultured with sinoatrial nodal cells (SANCs) can beat
in a synchronized manner and also express proteins like cardiac troponin T (cTnT)
and desmin. In these studies, prolonged co-culture of SANCs and CFs result in the
homeoprotein expression of NK2 homeo box 5 (Nkx2.5), which is a protein
exclusively expressed by cardiomyocytes. These studies hypothesize that SANCs
could help CFs transdifferentiate to cardiomyocytes and beat, with eventual loss
of pulsatility, which may be due to Nkx2.5 loss of binding to its receptor. To
prove this hypothesis there is a need of intensive study on early stage
differentiation to cardiomyocytes [72]. Heart failure (HF) is the cause of
highest mortality. Several HF- biomarkers such as, amino terminal pro-B type
natriuretic peptide (NT-pro BNP), galectin-3 (gal-3) and soluble(s) ST2, are used
for assessment of acute HF clinically by collecting peripheral venous (PV)
samples [73]. In chronic heart failure (CHF) by left ventricular remodeling was
because of several cytokines such as, IL-1-, IL-6 were elevated in
coronary sinus (CS) serum than PV of CHF patients, this indicated that these
cytokines were involved in heart failure. Where, NT-pro BNP concentration also
increased in the samples obtained from left ventricle in CHF patients. This
suggests that ventricular secretion of NT-proBNP cause CHF. Whereas, inflammatory
stimulation of pericardial mesothelial cells increases secretion of carbohydrate
antigen 125 (CA125) both in CS and PV. Hence, not only PV but CS level of CA125
and NT pro BNP would be used as biomarkers in CHF patients [74]. To overcome HF
there is device therapy, i.e., cardiac resynchronization therapy (CRT). However,
1/3rd of patients are non- responsive to CRT, hence there is a need to
evaluate biomarkers responsible for HF even after CRT. Usually, samples were
collected from PV to analyse biomarkers but sampling from the (CS) is more
prominent and useful than PV sampling. In the CS, biomarkers such as NT-pro BNP,
gal-3 and sST2 are significantly elevated, so it would possess a better
prognostic role [75].
6. Cardiac fibroblasts and cardiomyocytes senescence
Cellular senescence is the occurrence of cell cycle arrest at G1 phase and is
irreversible. It plays a prominent role in physiological and pathological
processes [76]. Adult CFs would decrease the electrophysiological and mechanical
function of co-cultured neonatal rat ventricular monocytes (NRVMs) through
downregulating the expression of ion channels, electrical coupling, calcium
handling and contraction related genes in the cardiac microenvironment [77].
Phenolic compounds (PCs) protect the heart from age-related detrimental effects
in age-related cardiac remodeling. PCs could ameliorate several hypertrophic
pathways such as calcineurin/nuclear factor of activated cells (NFATc3), CAMKII,
extracellular regulated kinase ½ (ERK ½) and glycogen
synthase kinase 3 (GSK3). Along with these effects, PCs reduce
the expression of plasma inflammatory and fibrotic markers. The P38 pathway is
regulated to ameliorate ECM remodeling. PCs exhibited reduced fibrosis by
downregulation of the pro-fibrotic TGF-1/Smad pathway
[78]. Recent research indicated that there exists senescence of CFs in a
post-natal day 1 (P1) neonatal mouse heart apical resection (AR) model, but the
senescent cells disappear at P21 when the hearts were fully restored.
Matricellular protein cellular communication network factor-1 (CCN1) has
upregulated expression in cardiomyocytes at P4 after AR. Knock down of CCN1 would
decrease cardiomyocytes and increase CFs. CCN1 is essential for senescence
induction of CFs and also helps in secretion of senescence associated secretory
phenotype factors such as IL-1a and IL-6 [79]. In infarcted or hypoxia treated
heart, fibroblasts show upregulated expression of P53, which is a senescent cell
target gene [80]. Ischemia and hypoxia-induced downregulation of sirtuin 1
(Sirt1) and neonatal rat cardiomyocytes (NRCMs) in mouse heart causing worsening
of heart function. Resveratrol (RSV) could reverse Sirt1 expression and cause P53
deacetylation resulting in reduction of senescent cardiomyocytes [81].
Plasminogen activator inhibitor-1 (PAI-1) is a prominent agent in the induction
of cellular senescence during aging and pathological conditions. TM544 is the
small molecule inhibitor of PAI-1 which inhibits cellular senescence caused by
doxorubicin (an anti-cancer drug) in cardiomyocytes, fibroblasts, and endothelial
cells, followed by the amelioration of anti-cancer-treatment-induced cardiac
toxicity [82]. Senescent cardiac fibroblasts express serine protease inhibitor E1
(SERPINE1), which regulates functional activity of cardiac endothelial cells
through deregulation of angiogenesis resulting in progression of cardiac
dysfunction [83].
7. Conclusions
CFs are a major component in the cardiac microenvironment.
Their interaction with cardiomyocytes and macrophages has been well studied, but
the mechanisms need to be further elucidated. Improved understanding of cardiac
development helped define some of these cues. Postn CFs that reside in
cardiac tissue as quiescent cells can be activated after injury, but the relation
and interaction between Postn CFs and other CFs in cardiac tissue need to
be elucidated. CFs acquire pulsatility when co-cultured with SANCs, but this
transition did not show persistence per electrophysiology. The mechanisms and
factors involved in the transition, which would contribute to persistent beating
of early cardiomyocytes formed from CFs, need to be elucidated. Moreover, the
relationship between cardiomyocyte senescence and CFs merit particular scientific
attention. CCN1’s function is well studied in neonatal heart. Elucidation of its
function in adult heart could contribute to future therapeutics.
Author contributions
RSL and LX drafted the manuscript under the supervision of FL, who edited and
approved the final version. RSL and YPZ drafted all figures. All authors
contributed to editorial changes in the manuscript. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
Not applicable.
Acknowledgment
We would like to express our gratitude to all those who helped us during the
writing of this manuscript and thank to all the peer reviewers for their opinions
and suggestions.
Funding
This work was supported by National Natural Science Foundation of China (Grant
No. 81871244), the Science and Technology Planning Social Development Project of
Zhenjiang City (SH2020030), the Natural Science Foundation of the Jiangsu Higher
Education Institutions of China (20KJB310010).
Conflict of interest
The authors declare no conflict of interest.